Patents by Inventor Gadi Gazit-Bornstein
Gadi Gazit-Bornstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9796779Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: GrantFiled: October 6, 2015Date of Patent: October 24, 2017Assignee: MedImmune LimitedInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiao-Dong Yang, Susan Ann Cartlidge, David William Tonge
-
Publication number: 20160090414Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: ApplicationFiled: October 6, 2015Publication date: March 31, 2016Inventors: Olivia RAEBER, Gadi GAZIT-BORNSTEIN, Xiao-Dong YANG, Susan Ann CARTLIDGE, David William TONGE
-
Patent number: 9181336Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: GrantFiled: March 14, 2013Date of Patent: November 10, 2015Assignee: MEDIMMUNE LIMITEDInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiao-Dong Yang, Susan Ann Cartlidge, David William Tonge
-
Patent number: 8697664Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.Type: GrantFiled: February 18, 2010Date of Patent: April 15, 2014Assignee: MedImmune LimitedInventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, Sue A. Cartlidge, David Charles Blakey
-
Publication number: 20130274450Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: ApplicationFiled: March 14, 2013Publication date: October 17, 2013Inventors: Olivia RAEBER, Gadi GAZIT-BORNSTEIN, Xiao-Dong YANG, Susan Ann CARTLIDGE, David William TONGE
-
Patent number: 8410058Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: GrantFiled: April 1, 2011Date of Patent: April 2, 2013Assignee: MedImmune LimitedInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiao-Dong Yang, Susan Ann Cartlidge, David William Tonge
-
Publication number: 20110200607Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: ApplicationFiled: April 1, 2011Publication date: August 18, 2011Applicant: MedImmune LimitedInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiaodong Yang, Susan Ann Cartlidge, David William Tonge
-
Publication number: 20110129412Abstract: Antibodies directed to the antigen CD20 and uses of such antibodies are disclosed herein. In particular, fully human monoclonal antibodies directed to the antigen CD20. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.Type: ApplicationFiled: May 25, 2006Publication date: June 2, 2011Inventors: Gadi Gazit-Bornstein, Larry J. Green, Xiao-Dong Yang, Christophe Queva, David Clarles Blakey, Mohammad Tabrizi
-
Patent number: 7939637Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: GrantFiled: December 8, 2006Date of Patent: May 10, 2011Assignee: MedImmune LimitedInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiaodong Yang, Susan Ann Cartlidge, David William Tonge
-
Publication number: 20100196398Abstract: The invention relates to targeted binding agents against CD105 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to CD105. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of CD105 and as diagnostics.Type: ApplicationFiled: September 18, 2009Publication date: August 5, 2010Applicant: MedImmune LLCInventors: GADI GAZIT-BORNSTEIN, NAOMI LAING, SIMON THOMAS BARRY, JOHN BABCOOK, QING ZHOU
-
Patent number: 7754859Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.Type: GrantFiled: August 3, 2007Date of Patent: July 13, 2010Assignee: AstraZeneca ABInventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Charles Blakey, Sue A. Cartlidge
-
Publication number: 20090324601Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.Type: ApplicationFiled: August 2, 2007Publication date: December 31, 2009Applicant: AstraZeneca ABInventors: David Charles Blakey, Susan Ann Cartlidge, Ian Foltz, Jaspal Singh Kang, Laura Taylor, Gadi Gazit-Bornstein, Naomi Laing
-
Patent number: 7423128Abstract: The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: November 3, 2004Date of Patent: September 9, 2008Assignee: Amgen Fremont Inc.Inventors: Gadi Gazit-Bornstein, Giorgio Senaldi, Xiao-Dong Yang, Bruce Keyt, Gerardo Zapata
-
Publication number: 20080089837Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.Type: ApplicationFiled: August 3, 2007Publication date: April 17, 2008Inventors: Naomi LAING, Jaspal Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Blakey, Sue Cartlidge
-
Publication number: 20070196376Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: ApplicationFiled: December 8, 2006Publication date: August 23, 2007Applicants: Amgen Fremont Inc., AstraZeneca, Global Intellectual PropertyInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiaodong Yang, Susan Cartlidge, David Tonge
-
Publication number: 20070014720Abstract: Antibodies directed to the antigen CD20 and uses of such antibodies are disclosed herein. In particular, fully human monoclonal antibodies directed to the antigen CD20. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.Type: ApplicationFiled: May 25, 2006Publication date: January 18, 2007Inventors: Gadi Gazit-Bornstein, Larry Green, Xiao-Dong Yang, Christophe Queva, David Blakey
-
Publication number: 20060093599Abstract: The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: ApplicationFiled: November 3, 2004Publication date: May 4, 2006Inventors: Gadi Gazit-Bornstein, Giorgio Senaldi, Xiao-Dong Yang, Bruce Keyt, Gerardo Zapata
-
Publication number: 20040141969Abstract: Embodiments of the invention described herein relate to antibodies directed to platelet derived growth factor-DD (PDGF-DD) and uses of such antibodies. The antibodies of the invention find use as diagnostics and as treatments for diseases associated with the overproduction of PDGF-DD. In particular, in accordance with embodiments of the invention, the use of anti-PDGF-DD antibodies for the treatment of nephritis and related disorders, including diseases caused by mesangial proliferation is provided.Type: ApplicationFiled: September 16, 2003Publication date: July 22, 2004Inventors: Juergen Floege, Gadi Gazit-Bornstein, Bruce A. Keyt, William J. LaRochelle, Henri Stephen Lichenstein